Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques

Cited by (432)

Items 101–200 of 432

1. Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses
   Jared E. Feldman, Julia Bals, Clara G. Altomare, Kerri St. Denis, Evan Christopher Lam, Blake Marie Hauser, Larance Ronsard, Maya Sangesland, Thalia Bracamonte Moreno, Vintus Okonkwo et al. · 2021 · Science Immunology
2. Prospects for SARS-CoV-2 diagnostics, therapeutics and vaccines in Africa
   Emmanuel Margolin, Wendy A. Burgers, Edward D. Sturrock, Marc Mendelson, Rosamund E. Chapman, Nicola Douglass, Anna‐Lise Williamson, Edward P. Rybicki · 2020 · Nature Reviews Microbiology
3. Are people with uncontrolled diabetes mellitus at high risk of reinfections with COVID-19?
   Rimesh Pal, Mainak Banerjee · 2020 · Primary care diabetes
4. Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications
   Endeshaw Chekol Abebe, Tadesse Asmamaw Dejenie · 2023 · Frontiers in Immunology
5. Cell and animal models of SARS-CoV-2 pathogenesis and immunity
   Sarah R. Leist, Alexandra Schäfer, David R. Martinez · 2020 · Disease Models & Mechanisms
6. Immunology of COVID ‐19
   Harald Brüssow · 2020 · Environmental Microbiology
7. Experimental re-infected cats do not transmit SARS-CoV-2
   N. Gaudreault, Mariano Carossino, I. Morozov, J. Trujillo, D. Meekins, Daniel W. Madden, K. Cool, B. Artiaga, Chester D. McDowell, D. Bold et al. · 2021 · bioRxiv
8. Insights into SARS-CoV-2 Persistence and Its Relevance
   Belete Ayele Desimmie, Yonas Raru, Hesham Awadh, Peimei He, Samson Teka, Kara S. Willenburg · 2021 · Viruses
9. Correlates of Vaccine-Induced Protection against SARS-CoV-2
   Till Koch, Sibylle C. Mellinghoff, Parichehr Shamsrizi, Marylyn M. Addo, Christine Dahlke · 2021 · Vaccines
10. Susceptibility and Attenuated Transmissibility of SARS-CoV-2 in Domestic Cats
    L. Bao, Zhi-Qi Song, Jing Xue, Hong Gao, Jiang-Ning Liu, Jie Wang, Qian Guo, Bin-Bin Zhao, Ya-Jin Qu, Fei-Fei Qi et al. · 2021 · Journal of Infectious Diseases
11. An inhaled bioadhesive hydrogel to shield non-human primates from SARS-CoV-2 infection
    Xuan Mei, Junlang Li, Zhenzhen Wang, Dashuai Zhu, Ke Huang, Shiqi Hu, Kristen D. Popowski, Ke Cheng · 2023 · Nature Materials
12. Impaired anti-SARS-CoV-2 antibody response in non-severe COVID-19 patients with diabetes mellitus: A preliminary report
    Rimesh Pal, Naresh Kumar Sachdeva, Soham Mukherjee, Vikas Suri, Deepy Zohmangaihi, Sant Ram, Goverdhan Dutt Puri, Ashish Bhalla, Shiv Lal Soni, Navin Pandey et al. · 2020 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
13. Mechanisms of Lung Injury Induced by SARS-CoV-2 Infection
    Samsara W. Upadhya, Jalees Rehman, Asrar B. Malik, Shuibing Chen · 2021 · Physiology
14. Fecal-oral transmission of SARS-CoV-2: A systematic review of evidence from epidemiological and experimental studies
    Martin Brink Termansen, Sebastian Frische · 2023 · American Journal of Infection Control
15. Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in golden Syrian hamster
    M. Brustolin, J. Rodón, M. L. Rodríguez de la Concepción, C. Ávila-Nieto, G. Cantero, M. Pérez, Nigeer Te, M. Noguera-Julián, V. Guallar, Alfonso Valencia et al. · 2021 · Emerging Microbes and Infections
16. Will SARS-CoV-2 Infection Elicit Long-Lasting Protective or Sterilising Immunity? Implications for Vaccine Strategies (2020)
    David S. Kim, S. Rowland-Jones, E. Gea-Mallorquí · 2020 · Frontiers in Immunology
17. Mapping SARS-CoV-2 Antibody Epitopes in COVID-19 Patients with a Multi-Coronavirus Protein Microarray
    D. Camerini, A. Randall, Krista Trappl-Kimmons, Amit Oberai, C. Hung, J. Edgar, A. Shandling, Vu T. Huynh, A. Teng, G. Hermanson et al. · 2021 · medRxiv
18. An Overview of Vaccines against SARS-CoV-2 in the COVID-19 Pandemic Era
    Alejandro Pascual‐Iglesias, Javier Cantón, Ana Maria Ortega‐Prieto, Jose M. Jiménez-Guardeño, José Ángel Regla-Nava · 2021 · Pathogens
19. Human Organoids and Organs‐on‐Chips for Addressing COVID‐19 Challenges
    Yaqing Wang, Peng Wang, Jianhua Qin · 2022 · Advanced Science
20. Neutralizing monoclonal antibodies for COVID-19 treatment and prevention
    J. Jaworski · 2020 · Biomedical Journal
21. Myeloid cell interferon responses correlate with clearance of SARS-CoV-2
    D. Singh, E. Aladyeva, Shibali Das, Bindu Singh, E. Esaulova, A. Swain, Mushtaq Ahmed, Journey Cole, Chivonne Moodley, S. Mehra et al. · 2022 · Nature Communications
22. Non-human primate models of human respiratory infections
    Julien Lemaître, Thibaut Naninck, Benoît Delache, Justina Creppy, Philippe Huber, Marion Holzapfel, Camille Bouillier, Vanessa Contreras, Frédéric Martinon, Nidhal Kahlaoui et al. · 2021 · Molecular Immunology
23. SARS-CoV-2–Specific Neutralizing Antibody Responses in Norwegian Health Care Workers After the First Wave of COVID-19 Pandemic: A Prospective Cohort Study
    Mai-Chi Trieu, Amit Bansal, Anders Madsen, Fan Zhou, Marianne Sævik, Juha Vahokoski, Karl Albert Brokstad, Florian Krammer, Camilla Tøndel, Kristin Greve-Isdahl Mohn et al. · 2020 · The Journal of Infectious Diseases
24. Lactiplantibacillus plantarum as a Potential Adjuvant and Delivery System for the Development of SARS-CoV-2 Oral Vaccines
    Julio Villena, Chang Li, María Guadalupe Vizoso-Pinto, Jacinto Sacur, Linzhu Ren, Haruki Kitazawa · 2021 · Microorganisms
25. Recruitment of highly cytotoxic CD8+ T cell receptors in mild SARS-CoV-2 infection
    Karolin I. Wagner, Laura Marlene Mateyka, Sebastian Jarosch, Vincent Grass, Simone Weber, Kilian Schober, Monika Hammel, Teresa Burrell, Behnam Naderi Kalali, Holger Poppert et al. · 2021 · Cell Reports
26. COVID ‐19 and plasma cells: Is there long‐lived protection?*
    Doan C. Nguyen, Pedro A. Lamothe, Matthew Charles Woodruff, Ankur Singh Saini, Caterina Elisa Faliti, Igñacio Sanz, Frances Eun-Hyung Lee · 2022 · Immunological Reviews
27. SARS-CoV-2 antibody testing for estimating COVID-19 prevalence in the population
    Thomas J. Vogl, Sigal Leviatan, Eran Segal · 2021 · Cell Reports Medicine
28. SARS-CoV-2 in animals: From potential hosts to animal models
    Anna Michelitsch, K. Wernike, Lorenz Ulrich, T. Mettenleiter, M. Beer · 2021 · Advances in Virus Research
29. Current Status of Putative Animal Sources of SARS-CoV-2 Infection in Humans: Wildlife, Domestic Animals and Pets
    Max Maurin, Florence Fenollar, Oleg Mediannikov, Bernard Davoust, Christian Albert Devaux, Didier Raoult · 2021 · Microorganisms
30. L-SIGN is a receptor on liver sinusoidal endothelial cells for SARS-CoV-2 virus
    Yuji Kondo, Jason L. Larabee, Liang Gao, Huiping Shi, Bojing Shao, Christopher Hoover, J. Michael McDaniel, Yen‐Chun Ho, Robert Silasi‐Mansat, Stephanie A. Archer‐Hartmann et al. · 2021 · JCI Insight
31. COVID-19 cynomolgus macaque model reflecting human COVID-19 pathological conditions
    E. Urano, T. Okamura, Chikako Ono, Shiori Ueno, S. Nagata, H. Kamada, Mahoko Higuchi, Mugi Furukawa, W. Kamitani, Y. Matsuura et al. · 2021 · Proceedings of the National Academy of Sciences of the United States of America
32. SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents
    Pablo García-Valtanen, Christopher M. Hope, Makutiro Ghislain Masavuli, Arthur Eng Lip Yeow, Harikrishnan Balachandran, Zelalem Addis Mekonnen, Zahraa Al-Delfi, Arunasingam Abayasingam, David Agapiou, Alberto Ospina Stella et al. · 2022 · Cell Reports Medicine
33. Durable antibody response one year after hospitalization for COVID-19: A longitudinal cohort study
    Mar Masiá, Marta Fernández‐González, Guillermo Telenti, Vanesa Agulló, José Alberto García, Sergio Padilla, Javier García‐Abellán, Antonio Galiana, Nieves Gonzalo-Jiménez, Félix Gutiérrez · 2021 · Journal of Autoimmunity
34. Harnessing Recent Advances in Synthetic DNA and Electroporation Technologies for Rapid Vaccine Development Against COVID-19 and Other Emerging Infectious Diseases
    Ziyang Xu, Ami R. Patel, Nicholas J. Tursi, Xi-Zhou Zhu, K. Muthumani, Daniel W. Kulp, D. Weiner · 2020 · Frontiers in Medical Technology
35. Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
    Ligong Lu, Hui Zhang, Meixiao Zhan, Jun Jiang, Hua Yin, Danielle J. Dauphars, Shi-You Li, Yong Li, You-Wen He · 2020 · Science China Life Sciences
36. Recovery from Acute SARS-CoV-2 Infection and Development of Anamnestic Immune Responses in T Cell-Depleted Rhesus Macaques
    K. Hasenkrug, F. Feldmann, Lara M. Myers, Mario L. Santiago, K. Guo, Bradley S. Barrett, Kaylee L. Mickens, A. Carmody, A. Okumura, Deepashri Rao et al. · 2021 · mBio
37. SARS-CoV-2 Vaccine Development: An Overview and Perspectives
    Yi Liu, Kai Wang, T. Massoud, R. Paulmurugan · 2020 · ACS Pharmacology & Translational Science
38. Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment
    Vivek P. Chavda, Normi D. Gajjar, Nirav Shah, Divyang J. Dave · 2021 · European Journal of Medicinal Chemistry Reports
39. Persistence of SARS-CoV-2-specific antibodies in COVID-19 patients
    Yanan Wang, Jingjing Li, Huijun Li, Ping Lei, Guanxin Shen, Chunguang Yang · 2020 · International Immunopharmacology
40. Neutralizing antibody-dependent and -independent immune responses against SARS-CoV-2 in cynomolgus macaques
    Hirohito Ishigaki, Misako Nakayama, Yoshinori Kitagawa, Cong Thanh Nguyen, Kaori Hayashi, Masanori Shiohara, Bin Gotoh, Yasushi Itoh · 2020 · Virology
41. Serological tests for COVID‐19: Potential opportunities
    Marcarious Moorkereh Tantuoyir, Nima Rezaei · 2020 · Cell Biology International
42. Exosome-Mediated mRNA Delivery For SARS-CoV-2 Vaccination
    Shang-Jui Tsai, Chen-Xu Guo, A. Sedgwick, Saravana Kanagavelu, Justin Nice, Sanjana Shetty, Connie Landaverde, Nadia A. Atai, S. Gould · 2020 · bioRxiv
43. Insights into neutralizing antibody responses in individuals exposed to SARS-CoV-2 in Chile
    C. Beltrán-Pavez, S. Riquelme-Barrios, A. Oyarzún-Arrau, A. Gaete-Argel, R. González-Stegmaier, Karina Cereceda-Solis, A. Aguirre, D. Travisany, R. Palma-Véjares, Gonzalo P. Barriga et al. · 2021 · Science Advances
44. SARS-CoV-2 immunity in animal models
    Zhaoming Chen, Yaochang Yuan, Qingtao Hu, Ai-Ru Zhu, Fenghua Chen, Shu Li, Xin Guan, Chao Lv, Tian Tang, Yi-Yun He et al. · 2024 · Cellular & Molecular Immunology
45. Seropositivity in blood donors and pregnant women during the first year of SARS‐CoV‐2 transmission in Stockholm, Sweden
    Xaquín Castro Dopico, Sandra Muschiol, Murray Christian, Leo Hanke, Daniel J. Sheward, Nastasiya F. Grinberg, Joanna Rorbach, Gordana Bogdanović, Gerald M. McInerney, Tobias Allander et al. · 2021 · Journal of Internal Medicine
46. Role of neutrophil chemoattractant CXCL5 in SARS-CoV-2 infection-induced lung inflammatory innate immune response in an in vivo hACE2 transfection mouse model
    Yan Liang, 中国医学科学院医学生物学研究所，云南 昆明650118，中国, Heng Li, Jing Li, Ze-Ning Yang, Jia-Li Li, Hui-Wen Zheng, Yan-Li Chen, Hai-Jing Shi, Lei Guo et al. · 2020 · 动物学研究
47. Mild SARS-CoV-2 infection in rhesus macaques is associated with viral control prior to antigen-specific T cell responses in tissues
    Christine E. Nelson, S. Namasivayam, Taylor W. Foreman, Keith D. Kauffman, Shunsuke Sakai, Danielle E. Dorosky, N. Lora, Kelsie Brooks, E. L. Potter, N. Garza et al. · 2022 · bioRxiv
48. Class I HLA Allele Predicted Restricted Antigenic Coverages for Spike and Nucleocapsid Proteins Are Associated With Deaths Related to COVID-19
    Marco Antônio M. Pretti, Rômulo Gonçalves Agostinho Galvani, Gustavo Fioravanti Vieira, Adriana Cesar Bonomo, Martín Bonamino, Mariana Boroni · 2020 · Frontiers in Immunology
49. Mechanisms of Dysregulated Humoral and Cellular Immunity by SARS-CoV-2
    N. Taefehshokr, Sina Taefehshokr, B. Heit · 2020 · Pathogens
50. A Synthetic Peptide CTL Vaccine Targeting Nucleocapsid Confers Protection from SARS-CoV-2 Challenge in Rhesus Macaques
    Paul E. Harris, Trevor Brasel, Christopher Massey, C.v. Herst, Scott Burkholz, Peter M. Lloyd, Tikoes Blankenberg, Thomas M. Bey, Richard T. Carback, Thomas W Hodge et al. · 2021 · Vaccines
51. Subtle differences in the pathogenicity of SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in rhesus macaques
    Vincent Jacobus Munster, Meaghan Flagg, Manmeet Singh, Claude Kwe Yinda, Brandi N. Williamson, Friederike Feldmann, Lizzette Pérez-Pérez, Jonathan E. Schulz, Beniah Brumbaugh, Myndi G. Holbrook et al. · 2021 · Science Advances
52. Animal models for SARS‐CoV‐2 infection and pathology
    Zhen-Fei Bi, Wei-Qi Hong, Jing-Yun Yang, Shuai-Yao Lu, Xiao-Zhong Peng · 2021 · MedComm
53. Neutralizing Antibodies and Cellular Immune Responses Against SARS-CoV-2 Sustained One and a Half Years After Natural Infection
    Lina Yan, Panpan Liu, Xu-gui Li, Shi-jing Zhou, Hao Li, Zhi-yin Wang, Feng Shen, Bichao Lu, Yu Long, Xiao Xiao et al. · 2022 · Frontiers in Microbiology
54. SARS CoV-2 infections in animals, two years into the pandemic
    Sara Frazzini, Massimo Amadori, Lauretta Turin, Federica Riva · 2022 · Archives of Virology
55. Experimental Models of SARS-CoV-2 Infection: Possible Platforms to Study COVID-19 Pathogenesis and Potential Treatments
    Sareh Pandamooz, Benjamin Jurek, Carl-Philipp Meinung, Zahra Baharvand, Alireza Sahebi Shahem-abadi, Silke Haerteis, Jaleel A. Miyan, James R. Downing, Mehdi Dianatpour, Afshin Borhani‐Haghighi et al. · 2021 · The Annual Review of Pharmacology and Toxicology
56. Selection of animal models for COVID-19 research
    Suresh Kumar, P. Yadav, R. Srinivasan, N. Perumal · 2020 · VirusDisease
57. Impaired Antibody-Dependent Cellular Cytotoxicity in a Spanish Cohort of Patients With COVID-19 Admitted to the ICU
    Lorena Vigón, Javier García‐Pérez, Sara Rodríguez-Mora, Montserrat Torres, Elena Mateos, María Castillo de la Osa, Miguel Cervero, Rosa Malo de Molina, Cristina Navarro, María Aránzazu Murciano-Antón et al. · 2021 · Frontiers in Immunology
58. Commercial Interferon-gamma release assay to assess the immune response to first and second doses of mRNA vaccine in previously COVID-19 infected versus uninfected individuals
    Nuria Tormo, David Navalpotro, María Martínez-Serrano, Marta Moreno, Fernando Grosson, Irene Tur, Maria Remedios Guna, Pepa Soriano, Ana Tornero, Concepción Gimeno · 2021 · Diagnostic Microbiology and Infectious Disease
59. Evolutionary rate of SARS-CoV-2 increases during zoonotic infection of farmed mink
    Ashleigh F. Porter, Damian F. J. Purcell, Benjamin P. Howden, Sebastián Duchêne · 2023 · Virus Evolution
60. Non-infectious status indicated by detectable IgG antibody to SARS-CoV-2
    David W. Denning, Anthony Kilcoyne, Cemal Ucer · 2020 · BDJ
61. What do we know about the antibody responses to SARS-CoV-2?
    Francisco Alejandro Lagunas‐Rangel, Venice Chávez‐Valencia · 2021 · Immunobiology
62. Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial
    Michiko Asano, Hiroshi Okada, Yohji Itoh, Hajime Hirata, Kensuke Ishikawa, Erika Yoshida, Akiko Matsui, Elizabeth J. Kelly, Kathryn Shoemaker, Urban Olsson et al. · 2021 · International Journal of Infectious Diseases
63. Comprehensive Comparison of Seven SARS-CoV-2-Specific Surrogate Virus Neutralization and Anti-Spike IgG Antibody Assays Using a Live-Virus Neutralization Assay as a Reference
    Marianne Graninger, Claudia Maria Jani, Elisabeth Reuberger, Katja Prüger, Philipp Gaspar, David Niklas Springer, Christian Borsodi, Lisa Weidner, Susanne Rabady, Elisabeth Puchhammer‐Stöckl et al. · 2023 · Microbiology Spectrum
64. Antigen-based multiplex strategies to discriminate SARS-CoV-2 natural and vaccine induced immunity from seasonal human coronavirus humoral responses
    Eric D. Laing, Spencer L. Sterling, Stephanie A Richard, Nusrat J Epsi, Si’Ana A. Coggins, Emily C Samuels, Shreshta Phogat, Lianying Yan, Nicole Moreno, Christian L. Coles et al. · 2021 · medRxiv
65. COVID-19 Research: Lessons from Non-Human Primate Models
    Laure Albrecht, Elodie Bishop, Basile Jay, Blaise Lafoux, Marie Minoves, Caroline Passaes · 2021 · Vaccines
66. Infection, recovery and re-infection of farmed mink with SARS-CoV-2
    Thomas Bruun Rasmussen, Jannik Fonager, Charlotte Sværke Jørgensen, Ria Lassaunière, Anne Sofie Hammer, Michelle Lauge Quaade, Anette Ella Boklund, Louise Lohse, Bertel Strandbygaard, Morten Rasmussen et al. · 2021 · PLoS Pathogens
67. Neutralizing antibody: a savior in the Covid-19 disease
    Sneh Lata Gupta, Rishi Kumar Jaiswal · 2022 · Molecular Biology Reports
68. PARIS and SPARTA: Finding the Achilles’ Heel of SARS-CoV-2
    Viviana R. Simon, Vamsi K Kota, Ryan F. Bloomquist, Hannah B. Hanley, David Forgacs, Savita G. Pahwa, Suresh Pallikkuth, Loren Gregory Miller, Joanna M. D. Schaenman, Michael R. Yeaman et al. · 2022 · mSphere
69. Liver transplantation in a patient after COVID-19 – Rapid loss of antibodies and prolonged viral RNA shedding
    Hanno Nieß, Nikolaus Börner, Maximilian Muenchhoff, Elham Khatamzas, Manfred J. Stangl, A. Graf, Philipp Girl, Enrico Georgi, Dionysios Koliogiannis, Gerald Denk et al. · 2020 · American Journal of Transplantation
70. The demography and characteristics of SARS-CoV-2 seropositive residents and staff of nursing homes for older adults in the Community of Madrid: the SeroSOS study
    Francisco Javier Candel, Pablo Barreiro, Jesús San Román, María del Mar Carretero, Juan Carlos Sanz, Marta Pérez-Abeledo, Belén Ramos, José Manuel Viñuela-Prieto, Jesús Canora, Francisco Javier Martínez-Peromingo et al. · 2021 · Age and Ageing
71. Integrated histopathological, lipidomic, and metabolomic profiles reveal mink is a useful animal model to mimic the pathogenicity of severe COVID-19 patients
    Zhiqi Song, Linlin Bao, Wei Deng, Jiangning Liu, Ren ErJun, Qi Lv, Mingya Liu, Feifei Qi, Ting Chen, Ran Deng et al. · 2022 · Signal Transduction and Targeted Therapy
72. Proteomic and phosphoproteomic profiling of COVID-19-associated lung and liver injury: a report based on rhesus macaques
    Jiang-Feng Liu, Yanan Zhou, Shuaiyao Lu, Ye-Hong Yang, Songfeng Wu, De‐Pei Liu, Xiaozhong Peng, Juntao Yang · 2022 · Signal Transduction and Targeted Therapy
73. Overview of Nonhuman Primate Models of SARS-CoV-2.
    A. Trichel · 2021 · Comparative medicine
74. Infection with SARS-CoV-2 can cause pancreatic impairment
    Wei Deng, Linlin Bao, Zhiqi Song, Ling Zhang, Pin Yü, Yanfeng Xu, Jue Wang, Wenjie Zhao, Xiuqin Zhang, Yunlin Han et al. · 2024 · Signal Transduction and Targeted Therapy
75. Long‐term monitoring of the development and extinction of IgA and IgG responses to SARS‐CoV‐2 infection
    А. В. Иванов, E. V. Semenova · 2021 · Journal of Medical Virology
76. IgG Antibodies Generation and Side Effects Caused by Ad5-nCoV Vaccine (CanSino Biologics) and BNT162b2 Vaccine (Pfizer/BioNTech) among Mexican Population
    Oscar Guzmán-Martínez, Kathia Guardado, Elsa Ladrón de Guevara, Saturnino Mezcua Navarro, Crescencio Hernández, Roberto Zenteno‐Cuevas, Hilda Montero · 2021 · Vaccines
77. Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2
    Ria Lassaunière, C. Polacek, G. Gram, Anders Frische, J. Tingstedt, Maren Krüger, B. Dorner, Anthony Cook, Renita Brown, Tatyana Orekov et al. · 2021 · npj Vaccines
78. Development of animal models for emerging infectious diseases by breaking the barrier of species susceptibility to human pathogens
    Na Rong, Jiangning Liu · 2023 · Emerging Microbes & Infections
79. Viruses That Can and Cannot Coexist With Humans and the Future of SARS-CoV-2
    Y. Furuse, H. Oshitani · 2020 · Frontiers in Microbiology
80. Bioengineered in Vitro Tissue Models to Study SARS-CoV-2 Pathogenesis and Therapeutic Validation
    Juhi Chakraborty, Indranil Banerjee, Raju Vaishya, Sourabh Ghosh · 2020 · ACS Biomaterials Science & Engineering
81. Medical imaging of pulmonary disease in SARS-CoV-2-exposed non-human primates
    M. Stammes, J. Lee, L. Meijer, Thibaut Naninck, L. Doyle-Meyers, Alexander G. White, H. Borish, A. Hartman, X. Alvarez, Shashank R. Ganatra et al. · 2021 · Trends in Molecular Medicine
82. Evaluation of the Levels of Peripheral CD3 + , CD4 + , and CD8 + T Cells and IgG and IgM Antibodies in COVID-19 Patients at Different Stages of Infection
    Waleed A. Aljabr, Ahod Al-Amari, Basma Abbas, Alaa Karkashan, Saad Saeed Alamri, Mohammed Alnamnakani, Athba Alqahtani · 2022 · Microbiology Spectrum
83. Cell and Animal Models for SARS-CoV-2 Research
    Eloïne Bestion, P. Halfon, S. Mezouar, J. Mege · 2022 · Viruses
84. Blockchain in Healthcare: A Decentralized Platform for Digital Health Passport of COVID-19 Based on Vaccination and Immunity Certificates
    Abdul Razzaq, Syed Agha Hassnain Mohsan, Shahbaz Ahmed Khan Ghayyur, Nouf Khalid Al-Kahtani, Hend Khalid Alkahtani, Samih M. Mostafa · 2022 · Healthcare
85. Characterisation and natural progression of SARS-CoV-2 infection in ferrets
    Gough G. Au, Glenn A. Marsh, Alexander J. McAuley, Suzanne L. Lowther, Lee Trinidad, Sarah Edwards, Shawn Todd, Jennifer A. Barr, Matthew P. Bruce, Timothy Poole et al. · 2022 · Scientific Reports
86. Challenges and Issues of Anti-SARS-CoV-2 Vaccines
    Sophie Blumental, Patrice Debré · 2021 · Frontiers in Medicine
87. Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques
    Wei Deng, Qi Lv, Fengdi Li, Jiangning Liu, Zhiqi Song, Feifei Qi, Qiang Wei, Pin Yü, Mingya Liu, Shasha Zhou et al. · 2022 · Signal Transduction and Targeted Therapy
88. SARS-CoV-2 immunity and vaccine strategies in people with HIV
    Claire Mullender, Kelly da Costa, Aljawharah Alrubayyi, Sarah Lilian Pett, Dimitra Peppa · 2022 · Oxford Open Immunology
89. A stable platform for the production of virus-like particles pseudotyped with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein
    Sylvie Roy, Karim Ghani, Pedro Otavio de Campos-Lima, Manuel Caruso · 2021 · Virus Research
90. Prevalence of COVID-19 Antibodies in Healthcare Workers at the Peak of the Pandemic in Mumbai, India: A Preliminary Study
    Tanu Singhal, Sweta Shah, Reshma Naik, Amreen Kazi, Pooja Thakkar · 2020 · Indian Journal of Medical Microbiology
91. Low antispike antibody levels correlate with poor outcomes in COVID‐19 breakthrough hospitalizations
    Devang K. Sanghavi, Shivang Bhakta, Hani M. Wadei, Wendelyn Bosch, Jennifer B. Cowart, Rickey E. Carter, Sadia Z Shah, Benjamin D. Pollock, Matthew R. Neville, Sven Peter Oman et al. · 2022 · Journal of Internal Medicine
92. ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models
    T. Lambe, Alexandra J. Spencer, Kelly M. Thomas, K. Gooch, Stephen R. Thomas, A. White, H. Humphries, Daniel Wright, Sandra Belij-Rammerstorfer, Nazia Thakur et al. · 2021 · Communications Biology
93. Novel ELISA Protocol Links Pre-Existing SARS-CoV-2 Reactive Antibodies With Endemic Coronavirus Immunity and Age and Reveals Improved Serologic Identification of Acute COVID-19 via Multi-Parameter Detection
    Rachel R. Yuen, Dylan Steiner, Riley M.F. Pihl, Elizabeth C. Chavez, Alex Olson, Erika L. Smith-Mahoney, Lillia A. Baird, Filiz T. Korkmaz, Patricia Urick, Manish Sagar et al. · 2021 · Frontiers in Immunology
94. Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants
    A. Chandrashekar, Jin-Yan Liu, Jing-You Yu, K. McMahan, Lisa H. Tostanoski, Catherine Jacob-Dolan, N. Mercado, Tochi Anioke, Aiquan Chang, Sarah Gardner et al. · 2021 · Science Translational Medicine
95. Characterisation of Particle Size and Viability of SARS-CoV-2 Aerosols from a Range of Nebuliser Types Using a Novel Sampling Technique
    S. Paton, Simon Clark, A. Spencer, I. Garratt, Ikshitaa Dinesh, Katy-Anne Thompson, A. Bennett, T. Pottage · 2022 · Viruses
96. Intranasal delivery of a rationally attenuated SARS-CoV-2 is immunogenic and protective in Syrian hamsters
    Shu-Feng Liu, C. Stauft, Prabhuanand Selvaraj, P. Chandrasekaran, F. D'agnillo, Chao-Kai Chou, Wells W. Wu, Christopher Z. Lien, Clement A. Meseda, Cyntia L Pedro et al. · 2022 · Nature Communications
97. Animal Models of COVID-19 II. Comparative Immunology
    R. Veenhuis, C. Zeiss · 2021 · ILAR journal
98. SARS-CoV-2 infection and disease outcomes in non-human primate models: advances and implications
    Lunzhi Yuan, Qiyi Tang, Huachen Zhu, Yi Guan, Tong Cheng, Ningshao Xia · 2021 · Emerging Microbes & Infections
99. Reinfections in COVID-19 Patients: Impact of Virus Genetic Variability and Host Immunity
    Aisha D. Fakhroo, Hebah A. Al-Khatib, Asmaa A. Al Thani, Hadi Mohamad Yassine · 2021 · Vaccines
100. Immune response induced by novel coronavirus infection
     Ying Sun, Yawen Zou, Haiyu Wang, Guangying Cui, Zujiang Yu, Zhigang Ren · 2022 · Frontiers in Cellular and Infection Microbiology